Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DL-AP5 是选择性 N-甲基-D-天冬氨酸 (NMDA) 受体拮抗剂的外消旋形式,具有抗惊厥作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 296 | 现货 | ||
5 mg | ¥ 698 | 现货 | ||
10 mg | ¥ 1,160 | 现货 | ||
25 mg | ¥ 2,490 | 现货 | ||
50 mg | ¥ 3,770 | 现货 | ||
100 mg | ¥ 5,420 | 现货 |
产品描述 | NMDA antagonist |
体内活性 | DL-AP5, a competitive NMDAR antagonist, on tramadol state-dependent memory.?A single-trial step-down passive avoidance task was used for the assessment of memory retrieval in adult male NMRI mice.?Post-training i.p. administration of an atypical μ-opioid receptor agonist, tramadol (2.5 and 5 mg/kg), dose-dependently induced impairment of memory retention.?Pre-test injection of tramadol (2.5 and 5 mg/kg) induced state-dependent retrieval of the memory acquired under post-training administration of tramadol (5 mg/kg) influence.?Pre-test intra-CA1 injection of NMDA (10-5 and 10-4 μg/mouse) 5 min before the administration of tramadol (5 mg/kg, i.p.) dose-dependently inhibited tramadol state-dependent memory.?Pre-test intra-CA1 injection of DL-AP5 (0.25 and 0.5 μg/mouse) reversed the memory impairment induced by post-training administration of tramadol (5 mg/kg).?Pre-test administration of DL-AP5 (0.25 and 0.5 μg/mouse) with an ineffective dose of tramadol (1.25 mg/kg) restored the retrieval and induced tramadol state-dependent memory.?It can be concluded that dorsal hippocampal NMDAR mechanisms play an important role in the modulation of tramadol state-dependent memory. |
别名 | DL-2-氨基-5-膦酰基缬草酸 |
分子量 | 197.13 |
分子式 | C5H12NO5P |
CAS No. | 76326-31-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 10 mM
DMSO: Insoluble
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O | 1 mM | 5.0728 mL | 25.364 mL | 50.7279 mL | 126.8199 mL |
5 mM | 1.0146 mL | 5.0728 mL | 10.1456 mL | 25.364 mL | |
10 mM | 0.5073 mL | 2.5364 mL | 5.0728 mL | 12.682 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
DL-AP5 76326-31-3 Neuroscience NMDAR 2-APV Retina Tonic pain Ganglion cells Ionotropic glutamate receptors Inhibitor DL-2-氨基-5-膦酰基缬草酸 inhibit DL-AP-5 Inhibition DL AP5 Antinociceptive activity iGluR DLAP5 inhibitor